Skip to content

Behavioral and neuroendocrine reactivity of smokers to smoking vs non-smoking avatars in virtual reality (SMoking AvataR Trial)

Behavioral and neuroendocrine reactivity of smokers to smoking vs non-smoking avatars in virtual reality (SMoking AvataR Trial) - SMART

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00025746
Enrollment
50
Registered
2021-09-01
Start date
2022-02-11
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F17.2

Interventions

Group 1: Intervention: Smoking Avatar Duration: about 20 minutes. Group 2: Control: Non-Smoking Avatar Duration: about 20 minutes.

Sponsors

Zentralinstitut für Seelische Gesundheit (ZI)
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Male sex, tobacco smoker.

Exclusion criteria

Exclusion criteria: Psychiatric comorbidity with psychiatric or psychotherapeutic treatment in the past 10 years (>1 psychiatric or psychotherapeutic treatment). Severe physical disease: cancer treatment during the past 10 years; metabolic disease (Addison's disease, Cushing's disease, hypogonadism, testosterone treatment); neurological disease (multiple sclerosis, Parkinson's disease, amyotrophic lateropathy, stroke during the past 5 years, traumatic brain disease with persistent neurological deficit); acute cardiovascular disease (first manifestation during the past 4 weeks), myocardial infarction, decompensated cardiac insufficiency; renal insufficiency; infectious disease currently being treated; rheumatological disease. Current use of medications for mental illness or use of drugs that interact with the central nervous system within a maximum of 5 half-lives. Known intolerance to high frequency flickering visual stimuli, as seen in very rare cases in certain forms of epilepsy (ascertainable through reported similar problems in past movie theater visits). Abstinence from cigarettes < 12 hours before planned study inclusion.

Design outcomes

Primary

MeasureTime frame
Explicit craving for smoking, implicit wanting of cigarette smoking (Implicit Association Test), approach behavior towards cigarette stimuli (Approach-Avoidance Test), selective attention toward cigarette stimuli (Dot-Probe Test) measured on three different occasions (smoking avatar vs non-smoking avatar; additionally: without an avatar).

Secondary

MeasureTime frame
Oxytocin, arginine-vasopressin, cortisol, and alpha-amylase in plasma and saliva on the following test conditions: smoking avatar vs non-smokign avatar; additionally without an avatar, before and after smoking.

Countries

Germany

Contacts

Public ContactKatharina Eidenmüller

Zentralinstitut für Seelische Gesundheit (ZI)

katharina.eidenmueller@zi-mannheim.de+621-17033827

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026